86315-69-7 Usage
Chemical structure
A chemical compound with an imidazo(4,5-c)pyridine core and a 2-methoxy-4-(methylthio)phenyl group attached to it.
Application
Used in medicinal research
Receptor interaction
Potent and selective agonist for the orexin receptors
Orexin receptors' function
Involved in the regulation of sleep, feeding, and arousal
Potential therapeutic uses
Treatment of sleep disorders and other conditions related to orexin dysfunction
Additional applications
Development of new drugs for neurological and psychiatric disorders
Research importance
Exploring the pharmacological properties and potential therapeutic uses to understand its impact on the human body
This list provides a summary of the key features and applications of CP-464416, highlighting its significance in medicinal research and potential therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 86315-69-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,6,3,1 and 5 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 86315-69:
(7*8)+(6*6)+(5*3)+(4*1)+(3*5)+(2*6)+(1*9)=147
147 % 10 = 7
So 86315-69-7 is a valid CAS Registry Number.
InChI:InChI=1/C14H13N3OS.ClH/c1-18-13-7-9(19-2)3-4-10(13)14-16-11-5-6-15-8-12(11)17-14;/h3-8H,1-2H3,(H,16,17);1H
86315-69-7Relevant articles and documents
Structure-activity relationships of arylimidazopyridine cardiotonics: Discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine
Robertson,Beedle,Krushinski,Pollock,Wilson,Wyss,Hayes
, p. 717 - 727 (2007/10/02)
Recently several noncatecholamine, nonglycoside cardiotonic drugs have been discovered that possess both inotropic and vasodilator activities in experimental animals and man. Prototypical compounds include amrinone, sulmazole, and fenoximone. We investigated the structural requirements necessary for optimal inotropic activity in a series of molecules containing a heterocyclic ring fused to 2-phenylimidazole and discovered that 2-phenylimidazo[4,5-c]pyridines were generally 5-10-fold more potent than analogous 2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H- imidazo[4,5-c]pyridine hydrochloride). The structure-activity relationship of this series is presented and compared to that of the imidazo[4,5-b]pyridine and purine series.
